000			01632 a2200445 4500
005			20250516083652.0
264		0	_c20120716
008			201207s 0 0 eng d
022			_a1879-114X
024	7		_a10.1016/j.clinthera.2012.02.002 _2doi
040			_aNLM _beng _cNLM
100	1		_aDempster, David W
245	0	0	_aRole of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. _h[electronic resource]
260			_bClinical therapeutics _cMar 2012
300			_a521-36 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAnimals
650	0	4	_aAntibodies, Monoclonal _xpharmacokinetics
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aBone Density _xdrug effects
650	0	4	_aBone Remodeling _xdrug effects
650	0	4	_aBone and Bones _xdrug effects
650	0	4	_aClinical Trials as Topic
650	0	4	_aDenosumab
650	0	4	_aDisease Models, Animal
650	0	4	_aDrug Evaluation, Preclinical
650	0	4	_aEstrogens _xdeficiency
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aOsteoporosis _xdrug therapy
650	0	4	_aOsteoporosis, Postmenopausal _xdrug therapy
650	0	4	_aRANK Ligand _xantagonists & inhibitors
650	0	4	_aTestosterone _xdeficiency
650	0	4	_aTreatment Outcome
700	1		_aLambing, Cheryl L
700	1		_aKostenuik, Paul J
700	1		_aGrauer, Andreas
773	0		_tClinical therapeutics _gvol. 34 _gno. 3 _gp. 521-36
856	4	0	_uhttps://doi.org/10.1016/j.clinthera.2012.02.002 _zAvailable from publisher's website
999			_c21644280 _d21644280